17.10.2023 • News

Thierry Van Nieuwenhove Appointed as CEO of Quotient Sciences

UK-headquartered drug development and manufacturing organization (CDMO) Quotient Sciences has appointed Thierry Van Nieuwenhove as its new CEO, effective Oct. 16, 2023. He succeeds Mark Egerton who retires after 18 years in this role.

As part of the leadership transition, the company also appointed Wayne Hewett as non-executive chairman.

Van Nieuwenhove, who has over 23 years of professional experience in the pharma/CDMO industry, joins Quotient from ABL where he was CEO for the last two years. Prior to this, he held various leadership roles in the CDMO industry, including Novasep, Lonza, and Minakem.

Hewett has more than three decades of board and leadership experience. He is currently chairman of CDMO Cambrex and serves on the board of directors of The Home Depot, Wells Fargo, UPS and Lytx, as well as a senior adviser to Permira.

Thierry Van Nieuwenhove, CEO, Quotient Sciences. Source: Quotient Sciences
Thierry Van Nieuwenhove, CEO, Quotient Sciences. Source: Quotient Sciences

Company

Quotient Sciences

Mere Way, Ruddington
NG11 6JS Nottingham
UK

Company contact







Interview

Navigating Uncertainty and Driving Innovation
Meeting Pharma’s Demand for Speed, Reliability, and Flexibility

Navigating Uncertainty and Driving Innovation

Axplora CCO Arul Ramadurai discusses navigating industry uncertainty, building strategic partnerships, and advancing flexible pharmaceutical manufacturing

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read